STOCK TITAN

Opaleye trims Eton Pharmaceuticals (ETON) stake with open-market sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc., reported open-market sales totaling 126,685 shares of common stock from July 2 to July 7, 2026. The trades were executed at weighted average prices around $37–$38 per share.

Shares were sold through Opaleye, L.P. and a separately managed account for which Opaleye Management serves as investment manager or portfolio manager. After these transactions, Opaleye, L.P. held 2,680,000 shares, and the managed account held 53,315 shares. Opaleye Management states it may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Opaleye Management Inc.
Role null
Sold 126,685 shs ($4.77M)
Type Security Shares Price Value
Sale Common Stock, par value $0.001 per share 20,000 $38.3728 $767K
Sale Common Stock, par value $0.001 per share 6,685 $38.3728 $257K
Sale Common Stock, par value $0.001 per share 10,000 $38.00 $380K
Sale Common Stock, par value $0.001 per share 65,000 $37.3851 $2.43M
Sale Common Stock, par value $0.001 per share 25,000 $37.3851 $935K
Holdings After Transaction: Common Stock, par value $0.001 per share — 2,680,000 shares (Indirect, By Opaleye, L.P.)
Footnotes (1)
  1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.05 to $37.85 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.565 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Total shares sold 126,685 shares Aggregate open-market sales July 2–7, 2026
Sale price (higher tranche) <money>$38.3728</money> per share Open-market sales on July 6–7, 2026
Sale price (lower tranche) <money>$37.3851</money> per share Open-market sales on July 2, 2026
Opaleye, L.P. holdings 2,680,000 shares Common stock held after July 7, 2026 sales
Managed account holdings 53,315 shares Common stock held after July 7, 2026 sales
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
separately managed account financial
"Securities owned by a separately managed account (the "Managed Account")."
A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.
beneficial ownership financial
"may be deemed to beneficially own the securities owned directly by the Fund."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider activity did Opaleye Management report for ETON in this Form 4?

Opaleye Management reported open-market sales totaling 126,685 Eton Pharmaceuticals shares. The trades occurred between July 2 and July 7, 2026, at weighted average prices around $37–$38 per share through a fund and a separately managed account.

At what prices were the recent Eton Pharmaceuticals (ETON) insider sales executed?

The reported Eton Pharmaceuticals shares were sold at weighted average prices near $37.39 and $38.37. Footnotes state individual trades ranged from $37.05 to $37.85 and from $38.00 to $38.565, reflecting multiple transactions within each price band.

How many Eton Pharmaceuticals shares did Opaleye, L.P. sell and still hold?

Opaleye, L.P. reported selling several blocks including 65,000, 25,000, 10,000 and 20,000 shares. Following these transactions, Opaleye, L.P. held 2,680,000 Eton Pharmaceuticals common shares, according to the share balances shown after each trade entry.

What are the Eton Pharmaceuticals holdings in the separately managed account?

A separately managed account associated with Opaleye Management sold 25,000 and 6,685 Eton Pharmaceuticals shares. After these open-market sales, the account’s reported position was 60,000 shares on July 2, 2026 and 53,315 shares on July 7, 2026, based on post-transaction balances.

Does Opaleye Management claim full beneficial ownership of the ETON shares?

Opaleye Management states it may be deemed to beneficially own shares held by Opaleye, L.P. and the managed account. However, it expressly disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest, limiting its ownership claim under Section 16 rules.

Were the Eton Pharmaceuticals (ETON) insider trades part of a derivative exercise?

No, all reported transactions involve non-derivative common stock sales. The Form 4 lists open-market sale code “S” for each trade and shows no derivative securities or option exercises, with the derivative transaction summary fields remaining empty in this filing.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Opaleye Management Inc.

(Last)(First)(Middle)
ONE BOSTON PLACE,
26TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02108

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.001 per share07/02/2026S65,000D$37.3851(3)2,710,000IBy Opaleye, L.P.(1)(5)
Common Stock, par value $0.001 per share07/02/2026S25,000D$37.3851(3)60,000IBy Managed Account(2)(5)
Common Stock, par value $0.001 per share07/06/2026S10,000D$382,700,000IBy Opaleye, L.P.(1)(5)
Common Stock, par value $0.001 per share07/07/2026S20,000D$38.3728(4)2,680,000IBy Opaleye, L.P.(1)(5)
Common Stock, par value $0.001 per share07/07/2026S6,685D$38.3728(4)53,315IBy Managed Account(2)(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account.
3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.05 to $37.85 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.565 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
5. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Opaleye Management, Inc., By: /s/ James Silverman, President07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)